U.S. patent law will have to adapt to the use of AI in the life sciences industry.
Justin T. Fleischacker
Advertisement
Articles by Justin T. Fleischacker
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Patients Avoid Care as Healthcare Costs Rise: Report
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
